Zacks Investment Research upgraded shares of SUPERNUS PHARMA (SUPN) from UNDERPERFORM to NEUTRAL on March 02, 2015, with a target price of $9.20.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
To get a free copy of the research report on SUPERNUS PHARMA (SUPN),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment